Lantheus Holdings (LNTH) Stock Price
Lantheus Holdings Price
Over the last 14 years Lantheus Holdings grew revenue by 11.0% annually, reaching 1.54 B USD. Earnings per share have grown at 19.5% per year over the last 9 years. For Lantheus Holdings, the net margin of 15.2% is up versus -16.8% a few years ago. The consensus 12-month price target for Lantheus Holdings is 102.50 USD, about 2.6% above where the stock trades today. Of 16 analysts, 8 rate the stock a buy — an overall Buy consensus.
Lantheus Holdings stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Lantheus Holdings business model & stock analysis
Frequently asked questions about Lantheus Holdings
The business model of Lantheus Holdings Inc revolves around the development, manufacturing, and commercialization of diagnostic medical imaging agents and products. Lantheus specializes in providing innovative diagnostic solutions to support healthcare professionals in accurately identifying and treating various medical conditions. The company leverages its expertise in medical imaging technology to create and distribute a diverse portfolio of contrast agents, including ultrasound and radiopharmaceutical imaging agents. Lantheus focuses on improving patient outcomes by delivering high-quality diagnostic imaging tools that aid in the detection and management of diseases.
Lantheus Holdings Inc is primarily active in the healthcare and pharmaceutical industries.
The main competitors of Lantheus Holdings Inc in the market include General Electric Healthcare, Bracco Imaging, and Bayer AG.
Lantheus Holdings Inc. is a leading medical imaging company founded in 1956. Headquartered in North Billerica, Massachusetts, Lantheus specializes in developing, manufacturing, and commercializing innovative diagnostic imaging agents and products. The company has a rich history of advancements in medical imaging technologies, including the creation of contrast agents for use with ultrasound and nuclear imaging procedures. Lantheus has built a solid reputation for delivering high-quality imaging solutions that help healthcare professionals make accurate diagnoses and improve patient care. With a strong commitment to research and development, Lantheus continues to drive advancements in medical imaging and remains a trusted name in the industry.
Lantheus Holdings Inc has achieved several significant milestones in its history. The company has successfully developed and commercialized innovative diagnostic imaging agents used in various medical fields. Lantheus Holdings Inc also expanded its global presence by establishing collaborations and partnerships with leading pharmaceutical companies. This has allowed the company to enhance its product portfolio and increase its market reach. Furthermore, Lantheus Holdings Inc has demonstrated consistent financial growth and stability, positioning itself as a trusted and reliable player in the healthcare industry. With its continuous focus on research and development, Lantheus Holdings Inc remains committed to advancing diagnostic imaging solutions for the benefit of patients and healthcare providers worldwide.
Lantheus Holdings Inc is primarily present in the United States.
Lantheus Holdings Inc represents a set of core values and embodies a corporate philosophy centered on excellence, innovation, and patient care. As a leading developer and manufacturer of diagnostic imaging agents, the company aims to improve medical outcomes and enhance patient well-being. Lantheus Holdings Inc prioritizes strong relationships with healthcare professionals and stakeholders to deliver safe, effective, and high-quality imaging solutions. With a commitment to advancing precision medicine, the company constantly strives to meet evolving medical needs by fostering collaboration, embracing technological advancements, and adhering to the highest ethical standards within the healthcare industry.
Analysts currently set an average price target of 105.27 USD for the Lantheus Holdings stock (median: 102.50 USD), implying +5.3 % versus the latest price. The consensus is based on 16 analyst ratings.
16 analysts currently rate the Lantheus Holdings stock: 8 recommend buying, 8 holding and 0 selling. For 2026, analysts expect Lantheus Holdings to generate revenue of 1.48 B USD and earnings per share of 5.59 USD.
Converted at the current exchange rate, the Lantheus Holdings share trades at 89.22 EUR (99.95 USD).
The Lantheus Holdings share (LNTH) is listed on 4 stock exchanges, including: NASDAQ (LNTH), Frankfurt (0L8.F), München (0L8.MU), Düsseldorf (0L8.DU).
Lantheus Holdings Inc. is a biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions. It was founded in 1956 and is headquartered in North Billerica, Massachusetts. Lantheus operates subsidiaries and branches worldwide to serve the global market. Lantheus operates in three business segments: Imaging, Radiopharmaceuticals, and Medical Isotopes. In the Imaging segment, the company offers diagnostic products for various applications. This includes contrast agents for several medical imaging technologies used to diagnose various diseases such as cardiovascular diseases, prostate cancer, and thyroid cancer. Imaging solutions offered include contrast agents for echocardiography and magnetic resonance imaging, as well as ultrasound and computer-aided detection solutions. In the Radiopharmaceuticals segment, Lantheus is one of the leading companies in the field. Radiopharmaceuticals are used for the fast and accurate diagnosis of various metabolic disorders and types of cancer. The products are developed in collaboration with partners and marketed under the TechneLite brand. TechneLite products are radiopharmaceuticals for myocardial perfusion scintigraphy, a commonly used method for diagnosing heart diseases. Lantheus also develops and produces Medical Isotopes for use in medical applications such as PET scans. The company offers a range of Medical Isotopes, including molybdenum-99. Lantheus' business model puts customers at the center. The company strives to offer innovative and high-quality products and services tailored to the needs of customers. Lantheus pursues an Agile Development strategy, which focuses on quickly implementing new product ideas. As a marketing strategy, Lantheus relies on differentiated competitive advantages. This means the company serves niches where there are few or no competitors. The use of radiopharmaceutical substances offers strong growth potential. However, competition in the market is relatively high. Overall, Lantheus is a leading company in the field of medical imaging and radiopharmaceuticals. With its innovative products and services, as well as agile development, the company aims to provide customers with the highest quality and optimal solutions tailored to their specific needs.
The expected revenue of Lantheus Holdings is 1.48 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Lantheus Holdings is 370.56 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Lantheus Holdings is currently 17.89. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Lantheus Holdings stock.
The price-to-sales ratio (P/S) of Lantheus Holdings is currently 4.47. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Lantheus Holdings stock.
The Eulerpool Quality Score for Lantheus Holdings is 6/10.
The ISIN of Lantheus Holdings is US5165441032. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Lantheus Holdings is A117UE. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Lantheus Holdings is LNTH. The ticker symbol is used to trade Lantheus Holdings shares on the stock exchange.
Lantheus Holdings stock
Lantheus Holdings Peer Group
Lantheus Holdings Ticker
Lantheus Holdings FIGI
All fundamentals and in-depth analysis of Lantheus Holdings
Our stock analysis for Lantheus Holdings stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lantheus Holdings. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.